{"id":78277,"date":"2026-05-08T22:53:22","date_gmt":"2026-05-08T22:53:22","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/78277\/"},"modified":"2026-05-08T22:53:22","modified_gmt":"2026-05-08T22:53:22","slug":"novo-nordisks-ozempic-india-price-cut-boosts-obesity-drug-sales","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/78277\/","title":{"rendered":"Novo Nordisk\u2019s Ozempic India Price Cut Boosts Obesity Drug Sales"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/NOVOB:DC\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novo Nordisk A\/S<\/a> saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2026-03-31\/novo-nordisk-india-cuts-prices-of-weight-loss-diabetes-drugs\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">steep price cuts<\/a> boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Sales of Wegovy, Ozempic and partner-branded versions rose to 32,000 units in April, according to market researcher Pharmarack, marking the first full month of data since generic semaglutide started selling in India. Novo Nordisk slashed starting-dose prices by 36% and 48%, respectively, from April 1, bringing both drugs down to 5,660 rupees ($60).<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last&hellip;\n","protected":false},"author":2,"featured_media":78278,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[227,174,691,16167,8063,41819,565,286,272,13578,4505,32380],"class_list":{"0":"post-78277","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-canada","9":"tag-china","10":"tag-drugs","11":"tag-eli-lilly-co","12":"tag-free-trade","13":"tag-generic-1st-sb-future","14":"tag-india","15":"tag-markets","16":"tag-novo-nordisk","17":"tag-novo-nordisk-a-s-b","18":"tag-switzerland","19":"tag-torrent-pharmaceuticals-ltd"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116541417531394857","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/78277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=78277"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/78277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/78278"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=78277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=78277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=78277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}